Review Timeline | CrossMark Policy | ClinMed Features
logo
International Journal of
Surgery Research and Practice ISSN: 2378-3397

Citation

Maher H, Zhang W, Chen K, Davies H, Cai X (2019) Current Status and Future Prospects of Idebenone in Treatment of Mitochondrial Diseases: Literature Review. Int J Surg Res Pract 6:102. doi.org/10.23937/2378-3397/1410102

Copyright

© 2019 Maher H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REVIEW ARTICLE | OPEN ACCESSDOI: 10.23937/2378-3397/1410102

Current Status and Future Prospects of Idebenone in Treatment of Mitochondrial Diseases: Literature Review

Hendi Maher, MD1, Weiwei Zhang2, Ke Chen, MD1, Henry Davies3 and Xiujun Cai, MD1*

1Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang Province, China

2Qilu Pharmaceutical Company, Limited, Jinan, Shandong, China

3Institute of Neuroscience, Zhejiang University School of Medicine, Hangzhou, China

Abstract

Idebenone (IDBN) is an antioxidant compound, structurally related to coenzyme Q10. It's therapeutic potential is growing in different areas. Over the two decades ago, for potential treatments of mitochondrial diseases have been suggested, relatively few have undergone controlled clinical trials. This review focuses on the recent history of manuscripts of idebenone, coenzyme Q10 and exercise in both primary disorders and secondary disorders. Despite prior clinical impressions that IDBN had a positive effect and significant benefit on Mitochondrial disorders.